Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì
  #31  
Ñòàðûé 04.09.2003, 10:22
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,270
Ïîáëàãîäàðèëè 33,170 ðàç(à) çà 31,520 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Ìèíà!
Ïîæàëóéñòà, íå íóæíî ïîêóïàòü íèêàêèõ îòå÷åñòâåííûõ (ðîññèéñêèõ) ëåêàðñòâ, ïî êðàéíåé ìåðå, îôëîêñèí ïðîèçâîäñòâà "Lechiva", íà ýòîì ïðåäïðèÿòèè ìàëî-ìàëüñêè ïðèäåðæèâàþòñÿ ìåæäóíàð.ñòàíäàðòîâ ISO 9000, îòå÷åñòâåííûå ëåêàðñòâà ìîæåò è íå ïîääåëûâàþò, íî òåõíîëîãèÿ ïðîèçâîäñòâà ìîæåò áûòü êðàéíå íåóäîâëåòâîðèòåëüíîé.
Ñ äðóãîé ñòîðîíû, â ñâîåé ïðàêòèêå, ÷àñòî ñòàëêèâàëñÿ ñ æåíùèíàìè, ó êîòîðûõ ðàçëè÷íûå õð. çàáîëåâàíèÿ ìî÷åïîëîâîé ñôåðû ñî÷åòàëèñü ñ æåëåçîäåôèöèòîì èëè ÆÄ àíåìèåé. Íå âäàâàÿñü â ïîäðîáíîñòè, òîëüêî çàìå÷ó, ÷òî â òàêèõ ñèòóàöèÿõ ìîæåò áûòü îñëàáëåí ëîêàëüíûé èììóíèòåò.
Åñëè Âû îáèëüíî ìåíñòðóèðóåòå, åäèòå íåìíîãî ìÿñà, ïðîáëåìû ñ íîãòÿìè, âîëîñàìè, ÷àñòî ïðîñòóæèâàåòåñü, ïîíèæåíà ðàáîòîñïîñîáíîñòü, ïàìÿòü, òî ýòî ìîæåò áûòü êëèí. ïðèçíàêàìè ÆÄ, â òàêîì ñëó÷àå, îïðåäåëèòå ñûâ. Æåëåçî, ÎÆÑÑ, æåëàòåëüíî ôåððèòèí è ñîîáùèòå. Êîððåêöèÿ ÆÄ ìîæåò ñíèçèòü ÷àñòîòó ðåöèäèâîâ çàáîëåâàíèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #32  
Ñòàðûé 04.09.2003, 11:38
mina mina âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.03.2003
Ñîîáùåíèé: 82
mina *
Cïàñèáî, äîêòîð. Ìîæåò áûòü, ïðè÷èíà, äåéñòâèòåëüíî â èììóíèòåòå? ß âåñíîé ëå÷èëà ãåïàòèò Ñ - ïåãàñèñ+ðèáàâèðèí, 14 íåäåëü (íàäî áûëî 24, íî ïðåðâàëè èç-çà ñåðäöà, êàøëÿ èòï.). Ñåé÷àñ ñäàëà íà ÏÖÐ (ñðàçó ïîñëå ëå÷åíèÿ áûë îòðèöàòåëüíûé). Íàäåÿëàñü, ÷òî èììóíèòåò õîòü êàê-òî óêðåïèëñÿ. Ìîæåò, ýòî ãåïàòèò è çäåñü íå äàåò ìíå ðàññëàáëÿòüñÿ, îõ. Âñå æå íàäî ñäàòü æåëåçî?

Êàê ðàç Ëå÷èâà ÿ è ïüþ, ñåé÷àñ ïåðåøëà íà 2 õ 400 â äåíü, áóäó ïèòü äî 14 äíåé. âäðóã ïîìîæåò
Îòâåòèòü ñ öèòèðîâàíèåì
  #33  
Ñòàðûé 04.09.2003, 12:43
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,270
Ïîáëàãîäàðèëè 33,170 ðàç(à) çà 31,520 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Àíòèãåïàòèòíîå ëå÷åíèå âðÿä ëè ìîæíî íàçâàòü èììóíîñòèìóëèðóþùèì, åñëè âñå æå õîòèòå ïåðåéòè íà áîëåå âûñîêèå äîçû îôëîêñàöèíà, äî ñëåäóåò ïîäóìàòü î ïðîôèëàêòèêå àíòèáèîòèê-âûçâàííîé äèàðåè, êîòîðàÿ ó Âàñ íàáëþäàëàñü íà ôîíå àçèòðîìèöèíà; ïîæàëóé, åñëè áóäåò ýôôåêò, òî õâàòèò è 4-6 äíåé. Æåëåçî îïðåäåëèòü ìîæåò áûòü è íóæíî, åñëè åñòü âûøåóêàçàííûå ñèìïòîìû òêàíåâîãî ÆÄ. Êñòàòè, êàê ó Âàñ ãåìîãëîáèí, ýðèòðîöèòû, íà ôîíå âûñîêîäîçíîé ðèáàâèðèíîòåðàïèè ìîæåò èíäóöèðîâàòüñÿ ãåìîëèòè÷åñêàÿ àíåìèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #34  
Ñòàðûé 04.09.2003, 13:21
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,270
Ïîáëàãîäàðèëè 33,170 ðàç(à) çà 31,520 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àëåêñåé Æèâîâ!

Ïîïðîáóþ ïðîÿñíèòü Âàì ñèòóàöèþ ïî îòäåëüíûì ïóíêòàì î èîãóðòàõ (î êàïñóëüíûõ ñòàíäàðòèçèðîâàííûõ ïðåïàðàòàõ ðå÷ü íå âåäåì) íà ïðèìåðå èíîïðèìåðîâ (äàáû Âû íå ãîâîðèëè, ÷òî ýòî ìîå ëè÷íîå èëè ÷àñòíîå ìíåíèå):
îá îäíîâðåìåííîì íàçíà÷åíèè èîãóðòîâ

J Antimicrob Chemother. 2003 Aug;52(2):308-11.
Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine.
Sullivan A, Barkholt L, Nord CE.
Department of Laboratory Medicine, Huddinge University Hospital, Karolinska Institutet, SE-141 86 Stockholm, Sweden.
OBJECTIVE: The objective of this study was to compare the effect of clindamycin on the intestinal microflora in subjects ingesting yogurt with added probiotic microorganisms with the microflora in subjects ingesting placebo yogurt. MATERIALS AND METHODS: Twenty-four healthy subjects were included in the study. All subjects received 150 mg clindamycin four times daily for 7 days and 250 ml yogurt twice daily for 14 days. Faecal samples were collected before, during and after administration of clindamycin. RESULTS: In the aerobic intestinal microflora, the numbers of enterococci increased after treatment in both groups, whereas other Gram-positive microorganisms decreased. In both groups, the numbers of Escherichia coli also decreased, whereas there was a concomitant increase in numbers of other Gram-negative bacilli. In the anaerobic microflora in subjects receiving yogurt with added microorganisms, the numbers of lactobacilli and bacteroides remained at the same levels throughout the study, whereas the numbers decreased in the placebo group. Other anaerobic bacteria decreased in both groups. The minimum inhibitory concentration of clindamycin against strains of bacteroides increased in both groups during the study. CONCLUSIONS: The probiotic microorganisms evaluated in this study prevented ecological disturbances in the numbers of intestinal Bacteroides fragilis group species during clindamycin administration.

Aliment Pharmacol Ther. 2002 Sep;16(9):1669-75.
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.

Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD.

Department of Internal Medicine, Medical College, National Cheng Kung University, Tainan, Taiwan.

AIM: To test whether supplements of Lactobacillus- and Bifidobacterium-containing yogurt (AB-Yogurt) affect the success of Helicobacter pylori eradication. METHODS: One hundred and sixty H. pylori-infected patients were randomized into a triple-plus-yogurt group or a triple-only group, receiving 1 week of triple therapy with and without supplements of AB-Yogurt, respectively. In the triple-plus-yogurt group, AB-Yogurt was continued for 4 weeks after triple therapy. Eight weeks later, patients were assessed for the success of H. pylori eradication. The stool samples of 22 randomly selected patients, 11 from each group, were provided on enrolment, at the first week and at the fifth week for evaluation of the percentage of Bifidobacterium in anaerobes. RESULTS: By intention-to-treat analysis, the triple-plus-yogurt group had a higher H. pylori eradication rate than the triple-only group (91% vs. 78%, P < 0.05). The per protocol H. pylori eradication rates were similar for both groups (93.5% vs. 89%, P = N.S.). Only patients supplemented with AB-Yogurt showed restoration of the percentage of Bifidobacterium in the anaerobes of stools at the fifth week to the level in the stools on enrolment. CONCLUSIONS: Supplement with AB-Yogurt can improve the intention-to-treat eradication rates of H. pylori, and can restore the depletion of Bifidobacterium in stools after triple therapy.

J Otolaryngol. 1995 Aug;24(4):230-3.
Effect of Lactobacillus acidophilus on antibiotic-associated gastrointestinal morbidity: a prospective randomized trial.

Witsell DL, Garrett CG, Yarbrough WG, Dorrestein SP, Drake AF, Weissler MC.

Vanderbilt Voice and Balance Center, Vanderbilt University, Nashville, Tennessee, USA.

Oral antibiotic therapy can alter the gastrointestinal microflora and result in troublesome gastrointestinal complaints. Patients who have experience with broad-spectrum antibiotics may be reluctant to start or to comply with antibiotic therapy due to the associated discomfort. In the field of otolaryngology, oral antibiotic therapy is commonplace, and patient intolerance of a particular antibiotic may result in compromise to a less effective choice.

***Yogurt, which contains Lactobacillus acidophilus, is often recommended by practitioners to help reduce the side effects of oral antibiotic therapy.***

We wanted to objectively evaluate the effect of orally administered L. acidophilus on the gastrointestinal side effects of oral broad-spectrum antibiotic therapy. Twenty-seven outpatients, 10 years of age or older, with ear, sinus, or throat infections, in whom amoxicillin/clavulanate was felt to be the antibiotic of choice, were randomly assigned to amoxicillin/clavulanate only, or amoxicillin/clavulanate and Lactobacillus treatment groups. Each patient was advised by the nursing staff to consume a well-balanced diet, and a detailed explanation of the medication schedule was given. A questionnaire was given to each patient at the conclusion of therapy. The data were analyzed using Spearman's rank-order correlations. Concomitant therapy of L. acidophilus with amoxicillin/clavulanate was associated with a significant decrease in patient complaints of gastrointestinal side effects and yeast superinfection. Almost all patients (89%) reported resolution of infection during the course of therapy. We believe that use of L. acidophilus is warranted in patients on broad-spectrum antibiotic therapy with gastrointestinal complaints.

Âàøå âíèìàíèå õî÷åòñÿ îáðàòèòü íà ìíîé âûäåëåííóþ ôðàçó â ïîñëåäíåì àáñòðàêòå: Èîãóðò(û), ñîäåðæàùèé (æèâûå) Lactobacillus acidophilus, ÷àñòî ðåêîìåíäóåòñÿ âðà÷àìè ïðàêòèêàìè ñ öåëüþ ñíèæåíèÿ ïîáî÷íûõ ýôôåêòîâ ïåðîpàëüíîé àíòèáèîòèêîòåðàïèè.
Òå, óæå íà óðîâåíü 1995 ãîäà ñóùåñòâóåò â ÑØÀ ïðàêòèêà íàçíà÷åíèÿ òàêîé ïðîôèëàêòèêè ñðåäè àìåðèêàíñêèõ âðà÷åé (íå ãîâîðÿ óæå î ñòàíäàðòèçèðîâàííûõ ïðîáèîòè÷åñêèõ ïðåïàðàòàõ - ñì. èíñòðóêöèè-âêëàäûøè ê îòä. ïðåïàðàòàì), êîíå÷íî æå, äàëåêî íå àáñîëþòíî âñåìè â òîé æå Àìåðèêå ýòî ïðèçíàåòñÿ. Ëîãè÷íî áóäåò è çäåñü íà ïîñòñîâåòñêîì ïðîñòðàíñòâå îäíèì äîêòîðàì ïðåäëàãàòü äàííûé âèä ïðîôèëàêòèêè, äàæå â èíòåðíåòå (Âàø ïîêîðíûé ñëóãà), à äðóãèì (â Âàøåì ëèöå) - îòíîñèòñÿ ê ýòîìó ñêåïòè÷åñêè.
Íî íå ñîâñåì êîëëåãèàëüíî, íà ìîé âçãëÿä, ïðèâîäèòü ñðàâíåíèå äàííîãî ïðàêòèêóåìîãî ìåòîäà ñ êåðîñèíîâûìè àïïëèêàöèÿìè èëè æå âûñìåèâàòü åãî òîëüêî ïîòîìó, ÷òî îí íå óêàçàí â îôèö. ðåêîìåíäàöèÿõ ïî ëå÷åíèþ ÇÏÏÏ. Äëÿ òàêèõ öåëåé áåðóòñÿ ìàíóàëû ïî àíòèáèîòèêîòåðàïèè èëè æå òåìàòè÷åñêèå ñòàòüè ïî ïðåäîòâðàùåíèþ ïîá. äåéñòâèÿ àíòèáèîòèêîòåðàïèè, íà ÷òî è ïîëàãàþñü â ñâîåé ïðàêòèêå.
Ñ íàèëó÷øèìè ïîæåëàíèÿìè â ñôåðå ïðîôåññèîíàëüíîãî ðîñòà,
Âàäèì.
PS. Êðîìå òîãî, ñóùåñòâóåò ïðàêòèêà íàçíà÷åíèÿ ëîêàëüíûõ àïïëèêàöèé èîãóðòîâ ñ æèâûìè êóëüòóðàìè (ñòðîãî ñòàíäàðòèçèðîâàííûå ïðîäóêòû ñ îïð. êîë-âîì ìèêðîîðãàíèçìîâ) êàê âñïîìîãàòåëüíàÿ òåðàïèÿ ê êîìïëåêñíîì ëå÷åíèè âàãèíèòîâ, íî ýòî òàê, äëÿ ñïðàâêè: íå âñå èîãóðòû îäèíàêîâî ïîëåçíû...
Îòâåòèòü ñ öèòèðîâàíèåì
  #35  
Ñòàðûé 04.09.2003, 15:46
Svetlana_V Svetlana_V âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 27.08.2001
Ãîðîä: Ìîñêâà, ÞÀÎ
Ñîîáùåíèé: 46
Svetlana_V *
Dr. Vad

íå âñå èîãóðòû îäèíàêîâî ïîëåçíû...

[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]

Îòëè÷íî ñêàçàíî![Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]
Îòâåòèòü ñ öèòèðîâàíèåì
  #36  
Ñòàðûé 04.09.2003, 17:53
mina mina âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.03.2003
Ñîîáùåíèé: 82
mina *
Cïàñèáî çà ñîâåòû, äîêòîð! ß ïüþ áèôèôîðì ñåé÷àñ, ãåìîãëîáèí 130, ýðèòðîöèòû â íîðìå, òîëüêî òðîìáîöèòû 132 ïðè íîðìå îò 160. ÑÕÓ è âîîáùå âñå ïåðå÷èñëåííîå Âàìè, êðîìå ïðîáëåì ñ íîãòÿìè, åñòü
Îòâåòèòü ñ öèòèðîâàíèåì
  #37  
Ñòàðûé 04.09.2003, 19:13
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,270
Ïîáëàãîäàðèëè 33,170 ðàç(à) çà 31,520 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 ïðèíöèïå, âûøåóêàçàííûå êëèí. ïðîÿâëåíèÿ ìîãóò áûòü îáóñëîâëåíû è íå ÆÄ, ïîýòîìó îñòàâëÿþ íà Âàøå óñìîòðåíèå îïðåäåëÿòü ëè òêàíåâûé ÆÄ, ïðè îòñóòñòâèè àíåìèè. Tðîìáîöèòîâ æåëàòåëüíî áû ïîáîëüøå, èõ ñíèæåíèå ìîæåò áûòü îáóñëîâëåíî ãèïåðñïëåíèçìîì (íåðåäêîå ÿâëåíèå ïðè çàáîëåâàíèÿõ ïå÷åíè).
Îòâåòèòü ñ öèòèðîâàíèåì
  #38  
Ñòàðûé 04.09.2003, 21:35
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàäèì,
Âû îïÿòü ïðèâåëè íàáîð íåêèõ ÷àñòíûõ ìíåíèé è äàííûå ïðåäâàðèòåëüíî-ïèëîòíûõ èññëåäîâàíèé.  êàêîì ìàíóàëå ïî àíòèáèîòèêîòåðàïèè ñîäåðæàòüñÿ ðåêîìåíäàöèè (íå óïîìèíàíèÿ è ïðåäïîëîæåíèÿ) ïî ïðèìåíåíèþ éîãóðòîâ (êîíêðåòíûå ïîêàçàíèÿ, ïðîòèâîïîêàçàíèÿ, äàííûå î ëåêàðñòâåííûõ èíòåðàêöèÿõ, äîçèðîâêè, êóðñû)? Ïðèâåäèòå ìíå ìàíóàëû ïî àíòèáèîòèêîòåðàïèè ãäå âîîáùå ãîâîðèòñÿ î ïðîáèîòèêàõ â òîì æå àñïåêòå? Çíàêîìû ëè Âàì äàííûå êîíòððîëèðóåìûõ ìíîãîöåíòðîâûõ èññëåäîâàíèé ïî ïðèìåíåíèþ éîãóðòîâ (âûáîðêè öèòèðîâàííûõ Âàìè ðàáîò íè÷òîæíî ìàëû)? Ñ÷èòàåòå ëè Âû ýòè÷íûìè ïóáëè÷íûå ðåêîìåíäàöèè (â èíåòå) ìåòîäîâ ëå÷åíèÿ ñ íåäîêàçàííîé ýôôåêòèâíîñòüþ è íåÿñíîé íåîáõîäèìîñòüþ èñïîëüçîâàíèÿ?  ýòîì ñìûñëå éîãóðòû îò àïïëèêàöèé êåðîñèíà ìàëî ÷åì îòëè÷àþòñÿ. Íå çàáóäåì åùå, ÷òî ìû ñ Âàìè ãîâîðèëè íå î ýðàäèêàöèè ãåëèêîáàêòåðà, à î ïðèìåíåíèè éîãóðòîâ â òåðàïèè îäíîé èç ÈÏÏÏ. È ïîòîì òî, ÷òî êåì òî ÷àñòî ðåêîìåíäóåòñÿ - íå åñòü ïðèçíàêî äîêàçàííîñòè ýôôåêòèâíîñòè ýòîãî ðåêîìåíäóåìîãî. Âàøè êîììåíòàðèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #39  
Ñòàðûé 05.09.2003, 16:42
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,270
Ïîáëàãîäàðèëè 33,170 ðàç(à) çà 31,520 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àëåêñåé!

Î ìàíóàëàõ: The use of antibiotics, ed.Kucers et al. 5th ed. 1997 (GB)

Bockus Gastroenterology, ed Haubrich W et al. 5th ed. 1995 (USA) "Antibiotic associated Injury to the Gut" - "Treatment" - "Bacteriotherapy"

çâèíÿéòå, áîëåå íîâîãî íè÷åãî íåò.

Äàëåå èç ïîñëåäíèõ îáçîðîâ:

Bartlett JG.
Clinical practice. Antibiotic-associated diarrhea.
N Engl J Med. 2002 Jan 31;346(5):334-9. Review.

Mylonakis E, Ryan ET, Calderwood SB.
Clostridium difficile--Associated diarrhea: A review.
Arch Intern Med. 2001 Feb 26;161(4):525-33

Madsen KL.
The use of probiotics in gastrointestinal disease.
Can J Gastroenterol. 2001 Dec;15(12):817-22.

Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J.
Protection from gastrointestinal diseases with the use of probiotics.
Am J Clin Nutr. 2001 Feb;73(2 Suppl):430S-436S.

Âñå ýòè ìåä. èñòî÷íèêè çíàíèé (ïîëàãàþ, âñå æå, ÷òî ýòî ìíåíèå ýêñïåðòîâ, à íå îòäåëüíî âçÿòûõ äîêòîðîâ, äàëåêèõ îò äèñêóòèðóåìîé ïðîáëåìû) ññûëàþòñÿ íà îäíè è òå æå ñòàòüè êàê òî:
McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL.
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.
Am J Gastroenterol. 1995 Mar;90(3):439-48.

McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al.
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.
JAMA. 1994 Jun 22-29;271(24):1913-8.

è èæå èì ïîäîáíûå, âûïîëíåííûå íà 120-200 ïàöèåíòàõ è ïî÷åìó-òî â îòäåëüíî âçÿòûõ öåíòðàõ, â òî âðåìÿ êàê ýôôåêò ìåòðîíèäàçîëà èëè âàíêîìèöèíà (â ñðàâíåíèè ñ ïëàöåáî) äëÿ ëå÷åíèÿ ÀÀÄ áûë ïîêàçàí íà ìåíåå 100 ïàöèåíòàõ è òîæå â åäèíè÷íûõ öåíòðàõ, îäíàêî îíè áûëè âêëþ÷åíû â àìåðèêàíñêèå ðåêîìåíäàöèè ïî ëå÷åíèþ CDAD (ÀÀÄ)- ñì. (Bartlett JG....), â òî âðåìÿ êàê ïðîáèîòèêè - íåò.
Îòâåò äî áàíàëüíîñòè ïðîñò - ïðåïàðàòû Saccharomyces boulardii are not available in USA (Mylonakis E...), êàê è íåêîòîðûå äð. âèäû ïðîáèîòèêîâ (ãëóïî áû áûëî ÷òî-ëèáî ðåêîìåíäîâàòü ñâîèì äîêòîðàì íåäîñòóïíîå).
Òàê, ÷òî ýôôåêòèâíîñòü ïî àìåðèêàíñêèì êàíîíàì ÅÂÌ ïîêàçàòü - ïîêàçàëè, à ðåêîìåíäîâàòü-òî íå÷åãî. Òîëüêî íå ñïðàøèâàéòå ïî÷åìó òàê ïîëó÷èëîñü - íå çíàþ.
 âèäó îòñóòñòâèÿ ìåæäóíàðîäíûõ ìíîãîöåíòðîâûõ èññëåäîâàíèé (ñïîíñèðîâàòü-òî êòî èõ áóäåò? ðàçðàáîò÷èêè? - íî ýòî íå ïàòåíòíûé ïðåïàðàò, øëåïàòü åãî ìîãóò âñå êîìó íå ëåíü, àññîöèàöèÿ ìèðîâûõ ìîëîêîçàâîäîâ?) äîêòîðà ìîãóò ðóêîâîäñòâîâàòüñÿ ðåçóëüòàòàìè ìåòà-àíàëèçîâ:

Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, Gasbarrini A.
Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea.
Aliment Pharmacol Ther. 2002 Aug;16(8):1461-7. Review.

D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ.
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.
BMJ. 2002 Jun 8;324(7350):1361. Review.

È ïðè÷åì âñå àâòîðû â îäèí ãîëîñ, îïèðàÿñü íà ïîëîæèòåëüíûé îïûò ïðèìåíåíèÿ, ïðèçûâàþò (êàê è Âû) ê ïðîâåäåíèþ ìíîãîöåíòðîâûõ èññëåäîâàíèé, à ÂÎÇ è íûíå òàì. (Ïðè÷èíû Âàì ïîíÿòíû, íàäåþñü)

È çàâåðøàÿ íàø ëèêáåç (èçâèíèòå, íî ïî äðóãîìó íå çíàþ êàê ýòî íàçâàòü, òê îòâåòû íà ìíîãèå Âàøè âîïðîñû Âû ìîãëè áû ñàìè íàéòè - íàâåðíîå, Âàì âìåñòî ýòîãî ãîðàçäî ïðèÿòíåå ïî÷ìóðèòü êîëëåãó) ïðåäëàãàþ Âàì ñâåäåíèÿ îäíîãî èç Åâðîôàðìàêîñïðàâî÷íèêîâ, ñ ïîêàçàíèÿìè ê ïðèìåíåíèþ ïðîáèîòè÷åñêèõ ïðåïàðàòîâ, çíàåòå, âñå æå íå Ðîññèÿ, ãäå â Âèäàëü ìîæíî ïðîòîëêíóòü ëþáîé ÁÀÄ ñ ëþáûì ïîêàçàíèåì:

Perenterol® 250 BIOCODEX
Saccharomyces boulardii lyophilisiert (entspricht 250 mg Hefepilz und 32,5 mg Lactose) 282,5 mg
Vorbeugung und Therapie von antibiotikabedingten Diarrh&ouml;en

Infloran Berna® DESMA HEALTHCARE
1 caps. contin.: Lactobacillus acidophilus viv. 10/9 , Bifidobacterium infantis 10/9 .
Als unterst&uuml;tzende Massnahme zur Wiederherstellung der Darmflora bei diarrhoischen und dyspeptischen Syndromen z.B. nach einer Therapie mit Antibiotika.

èçâèíèòå, ÷òî íà íåìåöêîì, äðóãîé ïîä ðóêîé íåò, íî äóìàþ, ïîíÿòíî.

Íà æèâûõ èîãóðòàõ, êîòîðûå íå ÿâëÿþòñÿ ëåêàðñòâåííûìè ïðåïàðàòàìè, íå óäàåòñÿ óáåäèòü èõ ïðîèçâîäèòåëåé íàïèñàòü ïîêàçàíèÿ è äîçèðîâêó.

Öèòàòà "Íå çàáóäåì åùå, ÷òî ìû ñ Âàìè ãîâîðèëè íå î ýðàäèêàöèè ãåëèêîáàêòåðà, à î ïðèìåíåíèè éîãóðòîâ â òåðàïèè îäíîé èç ÈÏÏÏ. "
Êàê ðàç ðå÷ü èçíà÷àëüíî âåëàñü î ïðîôèëàêòèêå ÀÀÄ èîãóðòàìè èëè äð. ïðîáèîòèêàìè, à íå óâåëè÷åíèè ýôôåêòèâíîñòè àíòèáàêòåðèàëüíîé òåðàïèè ïðîòèâ ÈÏÏÏ ïóòåì äîáàâëåíèÿ ïðîáèîòèêîâ, õîòÿ ïîâòîðþñü, ÷òî ñóùåñòâóþò ïóáëèêàöèè, ãäå ïðîáèîòèêè óëó÷øàëè ðåêîëîíèçàöèþ ïîëîâûõ ïóòåé, à òàêæå ïîêàçûâàþùèå íåêîòîðîå óñèëåíèå àíòèõåëèêîáàêòåðíîé ýðàäèêàöèè.

Àíàëîãè÷íàÿ ñèòóàöèÿ è ñ íàçíà÷åíèåì àñïèðèíà äëÿ ïðîôèëàêòèêè ÑÑÇ - âñå guidelines ïåñòðÿò ðåêîìåíäàöèÿìè, íî íèãäå â íèõ íå íàïèñàíî à êàê çàùèùàòü ñëèçèñòóþ îò ýðîçèðîâàíèÿ/ÿçâîîáðàçîâàíèÿ, äëÿ ýòîãî ñóùåñòâóþò òåìàòè÷åñêèå ïóáëèêàöèè èëè ëèòåðàòóðà.

 âèäó íàëè÷èÿ ìíîãî÷èñëåííûõ ýêñïåðòíûõ ïóáëèêàöèé â íîðìàëüíîé ìèðîâîé ëèòåðàòóðå, îñíîâàííûõ íà ðàáîòàõ, âûïîëíåííûõ ñ ñîáëþäåíèåì ñîâðåìåííûõ ïðèíöèïîâ ÅÂÌ, ñ÷èòàþ ýòè÷íûì çíàêîìèòü â èíòåðíåòå ïàöèåíòîâ ñ ýòîé èíôî è èìåþ ìîðàëüíîå ïðàâî ñîâåòîâàòü ïðèìåíÿòü ïðåïàðàòû ïðîáèîòèêîâ ïðè äëèòåëüíîé àíòèáèîòèêîòåðàïèè êàê ïîòåíöèàëüíîì ñðåäñòâå äëÿ ïðîôèëàêòèêè ÀÀÄ. Îïèðàÿñü íà îòäåëüíîå ìíåíèå îòäåëüíûõ êîëëåã èç-çà ðóáåæà, äîïóñêàþ âîçìîæíûì èñïîëüçîâàíèå ñ ýòîé öåëüþ èîãóðòû èëè äð. ìîë- ïðîäóêòû íå ïàñòåðèçîâàííûå, ñîäåðæàùèå æèâûå êóëüòóðû ëàêòî/áèôèäîáàêòåðèé. Âñåõ íåñîãëàñíûõ êîëëåã ïðîøó îñòàâàòüñÿ ïðè ñâîåì ìíåíèè èëè äîæèäàòüñÿ ïîÿâëåíèÿ òàêèõ ðåçóëüòàòîâ, êîòîðûå áû èì ïîçâîëèëè ïîìåíÿòü ñâîþ òî÷êó çðåíèÿ. Âñåõ ñîìíåâàþùèõñÿ - óáåäèòåëüíàÿ ïðîñüáà îñíàêîìèòüñÿ ñ èìåþùåéñÿ â ìèðîâûõ ìåä. àííàëàõ ðåëåâàíòíîé ëèòåðàòóðîé è ïîñëå àíàëèçà ñîñòàâèòü ñâîå ëè÷íîå ìíåíèå.

öèòàòà " ýòîì ñìûñëå éîãóðòû îò àïïëèêàöèé êåðîñèíà ìàëî ÷åì îòëè÷àþòñÿ"
ñ óäîâîëüñòâèåì îçíàêîìëþñü ñ Âàøèìè èñòî÷íèêàìè çíàíèé, ïîäòâåðæäàþùèõ äàííîå âûñêàçûâàíèå, èëè îïðîâåðãàþùåå ìîè èëè óêàçûâàþùèå íà íåáåçîïàñíîñòü/âðåäíîñòü òàêîé âñïîìîãàòåëüíîé òåðàïèè.
Ëè÷íî Âàøè ñîìíåíèÿ óæå âûñëóøàë, òàêæå îçíàêîìèëñÿ ñ çàðóáåæíûìè ïðèçûâàìè ê òðàéëàì, îõâàòûâàþùèì ïîëîâèíó íàñåëåíèÿ Çåìëè, îæèäàþ óñëûøàòü îò Âàñ ÷åãî-íèáóäü áîëåå ñîäåðæàòåëüíîãî.
Ïîõîæå, îäíèõ ðåêîìåíäàöèé ïî STD â ïðîòèâîâåñ áóäåò íå äîñòàòî÷íî...
Îòâåòèòü ñ öèòèðîâàíèåì
  #40  
Ñòàðûé 05.09.2003, 17:24
mina mina âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.03.2003
Ñîîáùåíèé: 82
mina *
Ìíå ìîé ãàñòðîýíòåðîëîã (ëå÷ó òàêæå õð. àêòèâíûé êîëèò), çàâîòä. ìåäèíñòèòóòà íàçíà÷èë áèôèôîðì âî âðåìÿ è ïîñëå àíòèáèîòèêîòåðàïèè, à òàêæå ãèàëàêò, ñóïïîçèòîðèè èòï, ïîñêîëüêó ïî àíàëèçó âèäíî, ÷òî ëàêòî - ñíèæåíèå, à áèôèäî - îòñóòñòâèå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #41  
Ñòàðûé 05.09.2003, 19:12
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Âûäåðæêè èç ñòàòüè
Åëåíû Óøêàëîâîé, êëèíè÷åñêîãî ôàðìàêîëîãà, êîîðäèíàòîðà Âñåðîññèéñêîé Èíôîðìàöèîííîé Ñåòè ïî Ëåêàðñòâåííûì Ñðåäñòâàì îò Ôàðìàêîïåéíîé Êîíâåíöèè ÑØÀ. 1999ã.
Ê ñîæàëåíèþ, â íàñòîÿùåå âðåìÿ, ïðîáëåìû îñâåùåííûå â ïðèâåäåííîé ñòàòüå òîëüêî óñóãóáëÿþòñÿ.

Àíòèáàêòåðèàëüíûå ñðåäñòâà ÿâëÿþòñÿ îäíîé èç íàèáîëåå øèðîêî èñïîëüçóåìûõ è äîðîãîñòîÿùèõ ãðóïï ëåêàðñòâåííûõ ñðåäñòâ, ïðèìåíÿåìûõ â ðàçëè÷íûõ îáëàñòÿõ êëèíè÷åñêîé ìåäèöèíû. Íà çàêóïêó àíòèáèîòèêîâ ðàñõîäóåòñÿ çíà÷èòåëüíàÿ ÷àñòü áþäæåòîâ ËÏÓ, âûäåëåííûõ íà ëåêàðñòâà. Çàòðàòû íà àíòèáèîòèêè ñîñòàâëÿþò â ñðåäíåì 25-50% îò çàòðàò íà âñå ëåêàðñòâà, çàêóïàåìûå áîëüíèöåé øèðîêîãî ïðîôèëÿ. Ðàñõîäû ëå÷åáíûõ ó÷ðåæäåíèé íà àíòèáèîòèêè ïîñòîÿííî ðàñòóò â ñâÿçè ñ ïîÿâëåíèåì íîâûõ äîðîãèõ ïðåïàðàòîâ. Ñòîèìîñòü 10-äíåâíîãî êóðñà òåðàïèè ñîâðåìåííûì àíòèáèîòèêîì ìîæåò äîñòèãàòü 1000-2000 äîëë. ÑØÀ. Ïî çàòðàòàì íà ëå÷åíèå èíôåêöèîííûå ïðîöåññû çàíèìàþò â áîëüíèöàõ îáùåãî ïðîôèëÿ ïåðâîå ìåñòî ñðåäè âñåõ ïàòîëîãèé.
Àíòèáèîòèêè îòíîñÿòñÿ ê ïðåïàðàòàì, èñïîëüçóåìûì íàèáîëåå íåðàöèîíàëüíî. Ïî äàííûì ÂÎÇ â ìèðå íåðàöèîíàëüíî íàçíà÷àþòñÿ ïðèìåðíî 75% ïðîòèâîìèêðîáíûõ ñðåäñòâ. Èññëåäîâàíèÿ ïîêàçûâàþò, ÷òî ÷àñòî àíòèáèîòèêè íàçíà÷àþòñÿ äëÿ ëå÷åíèÿ çàáîëåâàíèé, ïðè êîòîðûõ àíòèáàêòåðèàëüíàÿ òåðàïèÿ íå ïîêàçàíà. Íàïðèìåð, âðà÷è àìáóëàòîðíîé ïðàêòèêè ÑØÀ è Ôðàíöèè îêîëî òðåòè âñåõ àíòèáèîòèêîâ âûïèñûâàþò ïðè ïðîñòóäíûõ çàáîëåâàíèÿõ è èíôåêöèÿõ âåðõíèõ äûõàòåëüíûõ ïóòåé âèðóñíîé ýòèîëîãèè, ÷òî ñïîñîáñòâóåò ðàçâèòèþ áàêòåðèàëüíîé ðåçèñòåíòíîñòè è íàïðàñíîé òðàòå çíà÷èòåëüíûõ ôèíàíñîâûõ ñðåäñòâ. Ïî ïîäñ÷åòàì ñòîèìîñòü âûïèñûâàåìûõ ïðè ïðîñòóäíûõ çàáîëåâàíèÿõ àíòèáèîòèêîâ ñîñòàâëÿåò â ÑØÀ îêîëî 37,5 ìëí. äîëë. â ãîä.
Øèðîêîå íåîáîñíîâàííîå ïðèìåíåíèå àíòèáèîòèêîâ äëÿ ëå÷åíèÿ ïðîñòóäíûõ çàáîëåâàíèé, îñòðîãî ñðåäíåãî îòèòà, áðîíõèòà, ôàðèíãèòà ðàññìàòðèâàåòñÿ â êà÷åñòâå îäíîãî èç îñíîâíûõ ôàêòîðîâ, ñïîñîáñòâóþùèõ ðîñòó ìèêðîáíîé ðåçèñòåíòíîñòè.  ÷àñòíîñòè, íåðàöèîíàëüíîå ïðèìåíåíèå êîòðèìîêñàçîëà ïðè ñðåäíåì îòèòå ÿâëÿåòñÿ îñíîâíîé ïðè÷èíîé ýïèäåìèè ïíåâìîêîêêîâîé ðåçèñòåíòíîñòè, êîòîðàÿ â íàñòîÿùåå âðåìÿ ðàñïðîñòðàíÿåòñÿ âî âñåõ ðåãèîíàõ ìèðà. Ëå÷åíèå 1 ñëó÷àÿ îñòðîãî ñðåäíåãî îòèòà îáõîäèòñÿ â ÑØÀ â 115.8 äîëë.
×àñòî íåïðàâèëüíî îñóùåñòâëÿåòñÿ âûáîð ïðåïàðàòà, ïðîâîäèòñÿ ýìïèðè÷åñêàÿ òåðàïèÿ áåç âûäåëåíèÿ âîçáóäèòåëÿ è îïðåäåëåíèÿ åãî ÷óâñòâèòåëüíîñòè ê àíòèìèêðîáíûì ñðåäñòâàì. Êàê ïðàâèëî, òàêàÿ òåðàïèÿ ïðèâîäèò ê ÷ðåçìåðíîìó óïîòðåáëåíèþ äîðîãîñòîÿùèõ àíòèáèîòèêîâ ñ øèðîêèì ñïåêòðîì äåéñòâèÿ (êàðáàïåíåìîâ, öåôàëîñïîðèíîâ 3-åãî ïîêîëåíèÿ, ñîâðåìåííûõ àìèíîãëèêîçèäîâ è ò.ä.), íåðàöèîíàëüíîìó èñïîëüçîâàíèþ ôèíàíñîâûõ ñðåäñòâ, ðàçâèòèþ ðåçèñòåíòíîñòè ìèêðîîðãàíèçìîâ, à âî ìíîãèõ ñëó÷àÿõ è íåáåçîïàñíà äëÿ ïàöèåíòà.
 áîëüíèöàõ îáùåãî ïðîôèëÿ îò 30 äî 50% àíòèáèîòèêîâ ïðèìåíÿþòñÿ äëÿ ïðîôèëàêòèêè èíôåêöèîííûõ îñëîæíåíèé â õèðóðãèè, èç íèõ 30-90% èñïîëüçóþòñÿ íåðàöèîíàëüíî, îñîáåííî ñ òî÷êè çðåíèÿ âðåìåíè è ïðîäîëæèòåëüíîñòè ââåäåíèÿ.
Ïîáî÷íûå ýôôåêòû àíòèáèîòèêîâ ñîñòàâëÿþò ïðèìåðíî 25% îò âñåõ ïîáî÷íûõ ýôôåêòîâ ó ãîñïèòàëèçèðîâàííûõ áîëüíûõ. Ñåðüåçíûì îñëîæíåíèåì àíòèáàêòåðèàëüíîé òåðàïèè ÿâëÿåòñÿ ïñåâäîìåìáðàíîçíûé êîëèò, ÷àñòîòà ðàçâèòèÿ êîòîðîãî çíà÷èòåëüíî óâåëè÷èëàñü â ïîñëåäíèå ãîäû, ïðåæäå âñåãî â ñâÿçè ñ øèðîêèì è íåîáîñíîâàííûì ïðèìåíåíèåì â õèðóðãèè öåôàëîñïîðèíîâ 3 ïîêîëåíèÿ.
Íà ëå÷åíèå êàæäîãî ñëó÷àÿ ïñåâäîìåìáðàíîçíîãî êîëèòà ïî ðàñ÷åòàì, ïðîèçâåäåííûì â Âåëèêîáðèòàíèè, òðàòèòñÿ äîïîëíèòåëüíî áîëåå 4000 ôóíòîâ ñòåðëèíãîâ. Ëå÷åíèå îäíîé íåôðîòîêñè÷åñêîé ðåàêöèè, ðàçâèâàþùåéñÿ ïðè ïðèìåíåíèè àìèíîãëèêîçèäîâ è âàíêîìèöèíà, îáõîäèòñÿ â ÑØÀ â 2500 äîëëàðîâ (â öåíàõ 1990 ã.).  ðåçóëüòàòå ðåçèñòåíòíîñòè ê àíòèáèîòèêàì òîëüêî â ÑØÀ åæåãîäíî óìèðàåò îêîëî 60000 ÷åëîâåê è ðàñõîäóåòñÿ äîïîëíèòåëüíî 4 ìëðä. äîëëàðîâ.

P.S. Ñâåòëàíà!
Ýòè âûäåðæêè íå ïðîòèâ àíòèáèîòèêîâ, à ëèøü äëÿ ïîäòâåðæäåíèÿ ðàíåå âûñêàçàííîé ìûñëè, ÷òî àíòèáèîòèêè ñëåäóåò ïðèíèìàòü òîëüêî êîãäà îíè íåîáõîäèìû, à íå äëÿ ïðîôèëàêòèêè.
À åñëè óæ ïðèíèìàòü, òî îñîçíàíî (òåñò íà ÷óâñòâèòåëüíîñòü), à íå ïîòîìó ÷òî ïî ñòàòèñòèêå ýòîò ïðåïàðàò ïîìîã òðåì èç ïÿòè àíàëîãè÷íûì áîëüíûì èëè, òåì áîëåå, êàê Âû ñîáèðàëèñü: îäèí èç ïðîïèñàííûõ àíòèáèîòèêîâ íàâñêèäêó. Ó Âàñ íåò îáîñòðåíèÿ, ñðî÷íîñòè â ïðèåìå ëåêàðñòâ è ìîæåòå ñïîêîéíî ïîäîáðàòü îïòèìàëüíûé ïðåïàðàò. Äëÿ ìíîãèõ áàê. ëàáîðàòîðèé, íåñìîòðÿ íà óâåðåíèÿ ä-ðà Æèâîâà, ýòî ïîâñåäíåâíûé, îòðàáîòàííûé àíàëèç è ëå÷èòüñÿ, èìåÿ òàêèå äàííûå, íàäåæíåå, ÷åì èñõîäÿ èç ñòàòèñòèêè. Íî âñå ýòî ïðàâîìåðíî, åñëè äåéñòâèòåëüíî èìååò ìåñòî âÿëîòåêóùèé âîñïàëèòåëüíûé ïðîöåññ (ìíîãî ëåéêîöèòîâ), ñâÿçàííûé ñ óðåàïëàçìîé.  ïðîòèâíîì ñëó÷àå, ïðè áåðåìåííîñòè âàæíåå ñîñòîÿíèå îáùåé ñîïðîòèâëÿåìîñòè Âàøåãî îðãàíèçìà. Ê ïðèìåðó, äëèòåëüíî óíè÷òîæàÿ óðåàïëàçìó àíòèáèîòèêàìè, (äîïóñòèì ñðàçó íå ïîëó÷èòñÿ) Âû ìîæåòå «ïîñàäèòü» ñâîé èììóíèòåò. È òîãäà íå ýòà, òàê äðóãàÿ ñêðûòàÿ èíôåêöèÿ (íàïðèìåð, âèðóñíàÿ) âïîëíå ñìîæåò ïðîÿâèòüñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #42  
Ñòàðûé 05.09.2003, 19:34
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. Âàäèì,
Ó ìåíÿ ïðàâäà î÷åíü ìàëî âðåìåíè è âîçìîæíî Âû ñäåëàåòå îòäîëæåíèå è èçáàâèòå ìåíÿ îò ïîèñêà (íàçîâèòå ýòî ëèêáåçîì, ÿ íå Âëàäèìèð ßêîâëåâè÷, íå îáèæóñü). Âîçìîæíî ýòîìó ïîìîæåò áîëåå òî÷íàÿ ôîðìóëèðîâêà ìîèõ âîïðîñîâ. Åñëè ó âàñ íåò íà ýòè âîïðîñû ÷åòêèõ îòâåòîâ (ññûëêè, ëó÷øå êîíå÷íî öèòàòû), òî äàâàéòå íå áóäåì äðóã äðóãó ìîðî÷èòü ãîëîâó.

1.  êàêîì èç öèòèðîâàííûõ Âàìè ðóêîâîäñòâ ãîâîðèòñÿ î äîñòîâåðíî èçâåñòíîé ÷àñòîòå AAD ó áîëüíûõ ïîñëå ñòàíäàðòíîé òåðàïèè ÈÏÏÏ (èìåííî ýòî ÿ ðàñöåíèâàþ êàê ñóáúåêò ìîåãî îáðàùåíèÿ ê Âàì, à íå âîîáùå AAD è ïîñëå ëå÷åíèÿ àíòèáèîòèêàìè ÷åãî áû òî íè áûëî). Ïîæàëóéñòà åñëè ìîæíî ïðèâåäèòå âûäåðæêó.
2.  ñâÿçè ñ ïåðâûì âîïðîñàì, ñ÷èòàåòñÿ ëè ýòà ïðîáëåìà íàñòîëüêî àêòóàëüíîé è çíà÷èìîé äëÿ çäîðîâüÿ ÷åëîâåêà, ÷òîáû âñåì ïîäðÿä ðåêîìåíäîâàòü ïîñëå àíòèáèîòèêîâ (âìåñòå ñ àíòèáèîòèêàìè, äî àíòèáèîòèêîâ è ò.ä.) íåêîå ïðîôèëàêòè÷åñêîå ëå÷åíèå AAD? Èëè ìîæåò ëè áûòü éîãóðòîòåðàïèÿ ïî Âàøåìó ìíåíèþ ñòàíäàðòíîé ðåêîìåíäàöèåé äëÿ âñåõ áîëüíûõ, êîòîðûå ïðîõîäÿò ñòàíäàðòíûé êóðñ ëå÷åíèÿ ê.ë. ÈÏÏÏ?
3. Åñëè äà, òî ãäå èçëîæåíî (òî÷íàÿ öèòàòà è âûäåðæêà åñëè ìîæíî) êàê ýòà ïðîôèëàêòèêà éîãóðòàìè îñóùåñòâëÿåòñÿ è ïî÷åìó èìåííî òàê è íèêàê èíà÷å. Êàêîé äîëæåí áûòü éîãóðò è ÷òî îí äîëæåí ñîäåðæàòü, ñêîëüêî åãî íàäî åñòü (ïèòü), êàê îí ìîæåò ïîòåíöèàëüíî îòðàçèòüñÿ íà àêòèâíîñòè îäíîâðåìåííî (íàïðèìåð) ïðèìåíÿåìûõ àíòèáèîòèêîâ.

È ïîæàëóéñòà íå ãîíèòåñü çà êîëè÷åñòâîì ññûëîê. Íàçâàíèÿ ñòàòåé (ïóñòü èç ðåôåðèðóåìûõ æóðíàëîâ) è äàæå ìàíóàëîâ áåç èõ ñîäåðæàíèÿ íè÷åãî íå ãîâîðÿò. Äàâàéòå ïóñòü îäíó öèòàòó, íî èìåþùóþ ñàìîå ïðÿìîå îòíîøåíèå ê âîïðîñàì, êîòîðûå ÿ âàì çàäàë.

Ïî ïîâîäó Øòàòîâ. Ïîâåðüòå ýòî íå Ãâèíåÿ Áèñàó èëè Âåðõíÿÿ Âîëüòà. Åñëè ìåäèöèíñêèì ïðîôàññîöèàöèÿì è ýêñïåðòàì ýòîé ñòðàíû ñòàíåò ïîíÿòíî (áóäåò äîêàçàíî), ÷òî ñòðàíå íóæíû æèâûå éîãóðòû äëÿ ïðîôèëàêòèêè ñòîëü àêòóàëüíûõ AAD, ïðîèçâîäñòâî áóäåò íàëàæåíî âìèã è äîñòóïíîñòü áóäåò îáåñïå÷åíà. Íè÷åãî äðóãîãî, êðîìå îòñóòñòâèÿ îáîñíîâàííîé íåîáõîäèìîñòè â ýòèõ ïðîäóêòàõ äëÿ êëèíè÷åñêîé ìåäèöèíû â êà÷åñòâå ïðè÷èíû èõ îòñóòñòâèÿ íà àìåðèêàíñêîì ðûíêå ÿ íå âèæó. Ïðîùå ñêàçàòü ïîêà ñêîðåå âñåãî íå ïîíÿòíî çà÷åì ýòè éîãóðòû íóæíû. Ñòàíåò ïîíÿòíî, éîãóðòàìè çàâàëÿò ñòðàíó. Òîëüêî ïðî ôàðììàôèþ íå íàäî. Íàäåþñü Âû íå ðàçäåëÿåòå ýòè ïàðàíîÿëüíûå èäåè, ÷òî îíà äå óïðàâëÿåò àìåðèêàíñêîé ìåäèöèíîé.

ß áû õîòåë ïðèâëå÷ü ê ðàçãîâîðó íàøèõ êîëëåã, êîòîðûå èìåþò äåëî ñ àíòèáèîòèêîòåðàïèåé. Íàñêîëüêî àêòóàëüíûì ïðåäñòàâëÿåòñÿ íàø ñ Âàäèìîì ðàçãîâîð? ×òî Âû äóìàåòå íàñ÷åò îáÿçàòåëüíîñòè íàçíà÷åíèÿ éîãóðòîâ âñåì ïðèíèìàþùèì àíòèáèîòèêè è â ÷àñòíîñòè ïðîõîäÿùèì ñòàíäàðòíûå êóðñû ëå÷åíèÿ ÈÏÏÏ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #43  
Ñòàðûé 05.09.2003, 19:43
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âëàäèìèð ßêîâëåâè÷,
Ðîññèéñêóþ ëàáîðàòîðíóþ, à òî÷íåå ìèêðîáèîëîãè÷åñêóþ, êóõíþ (îñîáåííî â ÑÏá è Ìîñêåâ) ÿ çíàþ èçíóòðè óæå áîëåå 10 ëåò. Èç-çà ïîâñåìåñòíîé íèùåòû è îòñóòñòâèÿ êâàëèôèöèðîâàííûõ êàäðîâ, êóëüòèâèðîâàíèå ìèêîïëàçì-óðåàïëàçì ïðåäñòàâëÿåò äëÿ ïîäàâëÿþùåãî áîëüøèíñòâà ìèêðîáèîëîãè÷åñêèõ ëàáîðàòîðèé áîëüøóþ ïðîáëåìó. Ìíîãèå ëàáîðàòîðèè íå â ñîñòîÿíèè èçãòîâèòü äàæå ñîîòâåñòâóþùóþ ñòàíäàðòàì òðàíñïîðòíóþ ñðåäó, íå òîëüêî ñðåäó íà êîòîðîé ìîãóò ýòè ìèêðîîîãðàíèçìû ðàñòè. Î êà÷ñòâå ðîññèéñêèõ ÏÖÐ ïðàéìåðîâ ÷àñòî ïðèõîäèòñÿ òîëüêî äîãàäûâàòüñÿ, ò.ê. èõ íèêòî è íèêàêîé âíåøíåé ýêñïåðòíîé ñåðòèôèêàöèè íå ïîäâåðãàåò. Òàê ÷òî íå íàäî êàê âñåãäà ãîâîðèòü î òîì, î ÷åì ó Âàñ, äàëåêîãî îò êëèíè÷åñêîé ìåäèöèíû ÷åëîâåêà, åñòü ëèøü ïðèáëèçèòåëüíîå ïðåäñòàâëåíèå. Õîòÿ îïÿòü æå äëÿ îöåíêè ðåçóëüòàòîâ ïðîòèâîóðåàïëàçìåííîãî (íàïðèìåð) äåéñòâèÿ îçîíîòåðàïèè êà÷åñòâåííàÿ ëàáîðàòîðèÿ íå íóæíà. Âåäü äëÿ ïîäîáíûõ ìåòîäîâ "ëå÷åíèÿ", ÷åì áîëüøå âðåò ëàáîðàòîðèÿ, òåì êàê ïðàâèëî ëó÷øå ðåçóëüòàò. Ïîýòîìó òî ó Âàñ ïî-âèäèìîìó âñå òàê õîðîøî è ãëàäêî ñ ðîññèéñêèìè ëàáîðàòîðèÿìè, íå òàê ëè?
Îòâåòèòü ñ öèòèðîâàíèåì
  #44  
Ñòàðûé 05.09.2003, 20:12
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Àëåêñåé Âèêòîðîâè÷!
Ñ ó÷åòîì Âàøåãî ñòèëÿ âåäåíèÿ äèñêóññèè, ñ÷èòàéòå ìåíÿ, â äàëüíåéøåì, ïîëíîñòüþ ñîãëàñíûì ñî âñåì, ÷òîáû Âû íå ãîâîðèëè, ò. ê. âîçðàæàòü Âàì áîëüøå íå âèæó ñìûñëà.
Íî çäåñü, ðàç óæ çàâåë ðàçãîâîð, ñîîáùàþ, ÷òî âñåâîçìîæíûå áàê. ïîñåâû ëè÷íî ÿ, â îòëè÷èå îò Âàñ, äåëàë äîñòàòî÷íî ìíîãî. Áûëî áû èíòåðåñíî, åñëè íàçîâåòå êîíêðåòíûå áàê ëàáîðàòîðèè â Ìîñêâå, ñ êîòîðûìè Âàì òàê íå ïîâåçëî.
×òî êàñàåòñÿ îçîíîòåðàïèè, ñì. ýòó äèñêóññèè âûøå.

P.S. ß íå ñðåàãèðîâàë íà Âàø âûïàä â ìîé àäðåñ â äðóãîé äèñêóññèè, ãäå Âû ñîîáùèëè, ÷òî áåç ìàòåìàòèêè ìåäèöèíà íå íàóêà. Ïîýòîìó ñïåøó ñîîáùèòü äëÿ ïðèñóòñòâóþùèõ, ÷òî è â ìàòåìàòèêå Âû äîêà. Ïî êðàéíåé ìåðå, ìíå â ýòîì ïëàíå (êàê è âî âñåì îñòàëüíîì) äî Âàñ î÷åíü äàëåêî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #45  
Ñòàðûé 05.09.2003, 22:18
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âëàäèìèð ßêîâëåâè÷,
Äëÿ òîãî ÷òîáû ïîíèìàòü, ÷òî äîêàçàòü âîñïðîèçâîäèìîñòü è âçàèìîñâÿçü ñîáûòèé ìîæíî òîëüêî ñ ïîìîùüþ ìàòåìàòè÷åñêîãî àïïàðàòà, äîêîé â ìàòåìàòèêå áûòü íå íàäî. Âñå ãîðàçäî ïðîùå, íàäî ïðîñòî èìåòü ïðèìèòèâíûé çäðàâûé ñìûñë, êîòîðîìó ñëåäóåò áîëüøèíñòâî ðàçóìíûõ ëþäåé, â ò.÷. âðà÷åé.  ñâîå âðåìÿ, êîãäà ÿ çàíèìàëñÿ èññëåäîâàíèÿìè ñâÿçàííûìè ñ õëàìèäèéíîé èíôåêöèè, ÿ îáùàëñÿ ñ ëàáîðàòîðèåé ãäå çàâåäîâàë ïðîô. À. À. Øàòêèí (ê ñîæàëåíèþ óæå äàâíî ïîêîéíûé), îáùàëñÿ è ñ íèì ñàìèì (óìíåéøèé áûë ÷åëîâåê, ïûòàâøèéñÿ âûòàùèòü ðîññèéñêóþ ìèêðîáèîëîãèþ â öèâèëèçîâàííóþ êîìïàíèþ). Êàæåòñÿ ýòî áûë èí-ò ìèêðîáèîëîãèè èì. Ïàñòåðà (óæå áîëåå 10 ëåò ïðîøëî). Ìíå äîâîäèëîñü áåñåäîâàòü ñ âåñüìà âûñîêîêëàññíûìè ìèêðîáèîëîãàìè äàííîé ëàáîðàòîðèè è óñëûøàòü äîñòàòî÷íî î òîãäàøíèõ Ìîñêîâñêèõ ïðîáëåìàõ â ñôåðå ìèêðîáèîëîãèè. Ýòî æå ìíå óäàëîñü ñëûøàòü è îò ïðåäñòàâèòåëåé ÖÊÂÈ è 1-ãî ìåäà. Äóìàþ, ÷òî êàê è âåçäå çà 10 ëåò íàøà ìåäèöèíà (âêëþ÷àÿ ìèêðîáèîëîãèþ) ëó÷øå íå ñòàëà, ñêîðåå óñóãóáèëà ñâîè ïðîáëåìû. Ïðî Ïèòåð óæ íàäåþñü ïîâåðèòå, ÷òî çíàþ âñå àáñîëþòíî äîñêàíàëüíî. Âèäèòå ëè, Âëàäèìèð ßêîâëåâè÷. Âû èëè è âïðÿìü íå â ëàäàõ ñ ïðîñòûì çäðàâîì ñìûñëîì, èëè ïðîñòî ñêëîííû âåðèòü â ìèôû è äîãìû.  íèùåé ñòðàíå ãîâîðèòü î ëàáîðàòîðíîé (êàê è ëþáîé ïðîèçâîäñòâåííîé)áàçå â öèâèëèçîâàííîì ñìûñëå íå ïðèõîäèòñÿ. Âû ìíîãî çíàåòå ìîñêîâñêèõ ìèêðîáèîëîãè÷åñêèõ ëàáîðàòîðèé, êîòîðûå ðåàëüíî ïðîøëè çàïàäíûé àóäèò?  Ïèòåðå åñòü òîëüêî îäíà. À òî, ÷òî îíè î ñåáå ãîâîðÿò... Ãîâîðèòå è Âû.

 îòëè÷èå îò âàñ ÿ èìåþ âîçìîæíîñòü ñðàâíèâàòü ðåçóëüòàòû îò îäíèõ è òåõ æå áîëüíûõ, êîòîðûå ïîëó÷àþòñÿ â ðîññèéñêèõ ëàáîðàòîðèÿõ è íàïðèìåð àìåðèêàíñêèõ èëè ôèíñêèõ. Ðàçíèöà ÷àñòî ïðîñòî ïîòðÿñàåò. Ïðîâåðèë ýòî è íà ñåáå. Òàê ÷òî íå íàäî ãàëëþöèíèðîâàòü îòíîñèòåëüíî òîãî, ÷òî êàæäàÿ ðîññèéñêàÿ ëàáîðàòîðèÿ ñïîñîáíà ãðàìîòíî âûïîëíèòü ïîñåâ íà óðåàïëàçìû. ß óâåðåí, ÷òî 3 èç 5 ðîññèéñêèõ ìèêðîáèîëîãîâ âàì òîëêîì íå ðàññêàæóò ÷òî òàêîå âîîáùå óðåàïëàçìû. Îïÿòü æå ïðîâåðèë ñàì.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò


Îïöèè òåìû Ïîèñê â ýòîé òåìå
Ïîèñê â ýòîé òåìå:

Ðàñøèðåííûé ïîèñê
Îïöèè ïðîñìîòðà

Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 09:53.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.